OARSI 2016: IA 20mg & 40mg extended-release triamcinolone acetonide vs placebo for knee OA
Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: results from a double-blind, randomized, parallel-group, dose-ranging study
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
306 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to one of three groups for intra-articular injection: 20mg extended-release triamcinolone acetonide, 40mg extended-release acetonide (ER TCA), or placebo. The purpose of this study was to examine and compare the efficacy of groups based on pain reduction relative to baseline over the first 24 weeks post-injection....
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE